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lcohol abuse and dependence as 
well as less severe alcohol-related 
problems are associated with 
significant social costs. F
A
or example, 
in 1998 the social costs of alcohol 
abuse and dependence were estimated 
to be $184.6 billion (Harwood 2000). 
Although alcohol-abusing drinkers and 
their families bear some of these costs 
(e.g., medical and legal costs), the non-
abusing population also bears costs 
related to the adverse social consequences 
of problems such as alcohol-related 
motor vehicle crashes, crime, and 
increased health care costs. Because of 
these enormous societal costs, alcoholism1 
is a major concern among policymak-
ers and researchers. 
Traditionally, policymakers and 
researchers in the alcohol field have 
focused much of their attention on the 
effectiveness of treatment. However, in 
recent years managed care organizations 
have placed increasing emphasis on 
cost containment, which requires that 
these treatments also be cost-effective, 
thereby necessitating greater use of 
economic analyses of these services. To 
investigate the role of such economic 
analyses, the National Institute on 
Alcohol Abuse and Alcoholism’s 
(NIAAA’s) National Advisory Council 
formed a Subcommittee on Health 
Services Research. In its report to the 
Advisory Council, the Subcommittee 
noted that studies on the cost and cost-
effectiveness of alcoholism treatments 
are essential to ensuring that people 
with alcohol-related problems receive 
appropriate care and recommended 
that future research should compare 
the costs of alcoholism treatment pro-
grams with their outcomes and benefits 
(Subcommittee on Health Services 
Research 1997). 
In light of the heightened need for 
and emphasis on understanding the 
economic value of alcoholism treatment 
services, researchers increasingly are 
conducting economic evaluations of 
these services. This article presents an 
overview of economic analysis methods 
that currently are applied to alcohol 
services research, such as cost analysis, 
cost-effectiveness analysis, and cost– 
benefit analysis, including cost-offset 
studies. For each type of analysis, an 
1In this article, the term alcoholism is used to refer to all 
types of excessive alcohol consumption, regardless of
whether they meet the diagnostic criteria for alcohol
abuse and alcohol dependence. 
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overview of standard methods is provided, 
and their advantages and disadvantages 
are briefly discussed. The article concludes 
with a discussion of the methodological 
issues shaping the future direction of 
economic analyses in alcohol research. 
Methods of Economic 
Analysis 
In the alcohol field (as in other medical 
areas), the economic evaluation of health 
interventions involves three interrelated 
types of analyses, which are described 
further in the following sections: 
•	 Cost analyses, which estimate the 
resources used to deliver alcoholism 
treatment services and the monetary 
value of those resources to various 
stakeholders (e.g., society, treatment 
providers, or government funding 
agencies). 
•	 Cost-effectiveness analyses (CEAs), 
which are used to compare two or 
more treatment alternatives (one of 
which may be a no-treatment base­
line) in terms of both costs and 
effectiveness. 
•	 Cost–benefit analyses (CBAs), which 
directly compare the costs of a treat­
ment with the monetary value of the 
resulting outcomes. Because CBAs 
measure both costs and outcomes in 
monetary terms, they facilitate com­
parisons of alcoholism treatment 
services with other types of invest­
ments in health and well-being. 
For a summary of the features of these 
methods, see the table. 
Cost Analysis 
A cost analysis is the first step in a full 
economic evaluation of a treatment 
intervention and provides critical infor­
mation beyond its contribution to a 
CEA or CBA (Drummond et al. 1997). 
Ideally, cost analyses not only provide 
dollar estimates of the cost of alcoholism 
treatment services in a specific setting, 
but also offer information on the 
amount of resources (e.g., labor, facili­
ties, and supplies) used in providing 
those services. Only with this additional 
information on resources can the results 
be applied to different circumstances 
and adjusted to account for rising or 
declining prices. Cost studies also identify 
the resources (e.g., labor) that account 
for the largest share of the overall cost 
of treatment. This information allows 
policymakers to identify critical cost 
components and facilitates sensitivity 
analyses that assess whether the results 
of a CEA or CBA are affected by changes 
in key assumptions. Finally, cost studies 
compare the relative cost of one service 
to another, allowing policymakers to 
better allocate scarce treatment resources. 
To assess the relative economic mer­
its of various alcohol services accurately, 
it is imperative that the costs of the 
interventions be measured from the same 
perspective using similar and appropri­
ate methodologies. For example, 
accounting or actuarial cost estimation 
methods (which add up all expenses 
paid for by the program as well as all 
payments made to the program) focus 
on the actual expenses of a program. 
These approaches often can yield mis­
leading conclusions about program 
costs, however, because they ignore the 
value of volunteered or other “free” 
resources, such as volunteer labor or 
donated space or equipment. As a result, 
a program may appear to be relatively 
inexpensive simply because its building 
space was donated at zero cost to the 
program and some labor was supplied 
by volunteers. In contrast, economic 
costing methodologies are based on 
opportunity costs—the value of a good 
or service in its next-best use. For 
example, the opportunity cost of vol­
unteers’ time is the wage that those vol­
unteers could earn if they worked in a 
paying job instead of volunteering their 
time. When the opportunity costs of 
volunteered goods and services are 
included in the cost analysis, decision-
makers get a more accurate view of all 
the resources necessary to replicate the 
program in question. 
To ensure that program costs are 
consistently measured and all opportunity 
costs completely assessed, formal eco­
nomic cost studies rely on systematic 
cost collection tools. The first such tool 
to be used in the alcohol and other 
drug (AOD) abuse field was the Drug 
Abuse Treatment Cost Analysis Program 
(DATCAP), which was developed in 
the early 1990s by economists at RTI 
International (French et al. 1997). This 
tool estimates the total and per-patient 
costs of an AOD abuse treatment pro­
gram based on information on program 
revenue, patient flow, staffing, and 
other resource use. DATCAP has been 
used extensively in the AOD literature, 
and its systematic costing methodology 
facilitates comparison of program costs 
across a broad range of alcoholism 
treatment programs. 
A limitation of DATCAP is that it 
estimates the per-patient cost of a treat­
ment program without attempting to 
separate the costs of the individual 
component services (e.g., motivational 
interviewing, pharmacotherapy, or self-
help programs) that comprise that 
treatment program. Service-level cost 
estimates are critical to sound policy 
decisions, however, because different 
treatment programs may use different 
combinations of services. 
Recognizing DATCAP’s limitation, 
Zarkin and colleagues (2004) developed 
the Substance Abuse Services Cost 
Analysis Program (SASCAP), which 
includes two components: 
•	 A cost survey (SASCAP–Cost) to 
collect data on program costs and 
revenue 
•	 A labor allocation survey (SASCAP– 
Labor) to collect data on staff time 
allocated across various treatment 
services. 
Using both components, researchers 
can estimate the costs of discrete treat­
ment services as well as the average 
costs per patient. This new approach 
to estimating the costs of treatment ser­
vices yields estimates that include not 
only the cost of direct labor but also 
the cost of indirect labor (e.g., adminis­
trative staff ) and nonlabor resources. 
In addition, the indirect labor costs 
explicitly include the costs of adminis­
trative services (e.g., human resources, 
legal fees, billing, and marketing) 
provided to the program by a parent 
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organization, which represents an advance 
over previous cost estimation studies. 
Although tools such as DATCAP 
and SASCAP greatly facilitate economic 
cost studies of alcoholism treatment 
programs, standardized cost studies still 
pose many challenges for researchers. 
Perhaps the greatest of these is the bur­
den on both researchers and program 
staff in terms of completing a standard­
ized cost instrument. For example, 
DATCAP takes approximately 8 to 16 
person-hours to complete (including 
both preparation and interview time) 
and should be administered by a trained 
economist (French 2003). SASCAP 
is less burdensome than DATCAP, but 
the time necessary to complete it still is 
a concern. Anecdotal evidence suggests 
that program staff spent an average of 
4 to 5 hours completing both SASCAP 
components (Zarkin et al. 2004). How­
ever, SASCAP can be administered by 
noneconomists. 
Although the term cost study has 
been used for more than a decade in 
the alcohol services research literature, 
formal economic cost analyses are a rel­
atively new addition to alcohol services 
research. Most cost studies described in 
the alcoholism treatment literature are 
components of CEAs or CBAs. For 
example, formal cost studies have been 
discussed as part of economic evaluations 
of screening and brief intervention for 
hazardous alcohol use (e.g., Fleming et 
al. 2000; Wutzke et al. 2001). Increasingly, 
however, formal economic cost studies 
are being published as stand-alone 
analyses (e.g., Cisler et al. 1998; Zarkin 
et al. 2003, 2005). 
Cost-Effectiveness Analysis 
CEAs compare two or more treatments 
using the cost-effectiveness ratio—the 
difference in costs between two inter­
ventions divided by the difference in 
outcomes (Gold et al. 1996). In other 
words, the cost-effectiveness ratio reflects 
how much more it costs to achieve 
one additional unit of outcome with 
one treatment intervention than with 
another intervention. For example, a 
cost-effectiveness ratio could show that 
alcohol intervention A costs $1,000 
more than intervention B for every 
additional day of abstinence achieved. 
Although the cost-effectiveness ratio 
is a useful summary of both the costs 
and effectiveness of an intervention, it 
does not necessarily provide decision-
makers with definitive policy recom­
mendations. It is tempting to say that 
the intervention with the lowest cost-
effectiveness ratio should be adopted, 
but if stakeholders value the outcome 
highly, then it may be more beneficial 
to use an intervention with a higher 
cost-effectiveness ratio. Economists 
refer to the implicit value that decision-
makers assign to an outcome as the 
decisionmakers’ willingness to pay for 
that outcome. The most desirable 
intervention among a set of mutually 
exclusive choices is the most effective 
intervention with an incremental cost-
effectiveness ratio that is less than the 
decisionmaker’s willingness to pay for 
the intervention, excluding dominated 
interventions (Johannesson and Weinstein 
1993; Bala and Zarkin 2002; Gold 
et al. 1996). An intervention may be 
dominated in either a simple sense 
(higher cost and lower effectiveness 
than another option) or in an extended 
sense (higher cost-effectiveness ratio than 
a more effective or less expensive option). 
For a clear and concise summary of the 
decision rules to use when interpreting 
CEAs, see Bala and Zarkin (2002).  
The choice of outcome to be ana­
lyzed is a key issue when using CEAs. 
Some authors (e.g., Drummond et al. 
1997) have argued that any clinical or 
policy-relevant outcome, such as per­
centage of abstinent days, can be used 
if it is relevant for all interventions 
under consideration. Sindelar and col­
leagues (2004), however, have posited 
that AOD treatments often yield 
numerous worthwhile outcomes which 
are not always correlated. As a result, 
the cost-effectiveness ratio for one out­
come measure may yield a different 
policy implication than the ratio for 
another outcome measure. One solution 
to this problem is to use a common 
metric such as the quality-adjusted life 
year (QALY) as the outcome (Gold et 
al. 1996). QALYs assign a quality-of­
life weight to each additional year of 
life generated by a treatment, with a 
weight of 1.0 indicating perfect health 
and a weight of 0 indicating death. An 
advantage of QALYs is that they can be 
used to compare a wide range of pro­
grams with each other, even services as 
diverse as alcoholism treatment and 
blood pressure screening. A problem 
with using QALYs, however, is that 
they can be difficult to estimate, espe­
cially for services which are expected to 
have only small effects on the patients’ 
quality of life in the near term. 
CEAs have been employed in alco­
hol services research for a long time 
(for a historical review, see French 2001; 
for recent examples, see Chisholm et al. 
2004; Corry et al. 2004; Kaskutas et al. 
2004; Palmer et al. 2000). Most CEAs 
of alcohol services compare more 
intensive treatment (e.g., inpatient) 
with less intensive treatment (e.g., par­
tial hospitalization) (e.g., McCrady et 
al. 1986; Kaskutas et al. 2004). More 
recent studies also have examined the 
cost-effectiveness of pharmacotherapies 
for alcohol dependence (e.g., Schädlich 
and Brecht 1998) or of screening and 
brief intervention (Wutzke et al. 2001). 
In general, most studies have found 
that less intensive treatments may be 
more cost-effective than more intensive 
treatments (French 2001). Some inves­
tigators have raised concerns about these 
conclusions, however, because the stan­
dard analytic methods used in these 
studies do not account for subgroups 
of patients who may benefit dispropor­
tionately from more intensive treat­
ments (Bray et al. 2004). 
Cost–Benefit Analysis 
Conceptually, CBAs not only calculate 
the costs of treatment but also place a 
dollar value on all outcomes (e.g., the 
value of avoided car crashes or reduced 
health care costs). As a result, the dollar 
value of the benefits associated with a 
treatment program can be directly 
compared with the dollar value of the 
program’s costs (Drummond et al. 
1997). In practice, however, not all 
outcomes are assigned a dollar value 
(i.e., are monetized). Depending on 
which specific outcomes are monetized, 
CBA studies also may be referred to as 
cost-offset studies (which typically use 
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Methods for Analyzing the Economic Costs and Benefits of Health Services 
Definition Comments/Tools Used Advantages Disadvantages 
Cost Analysis 
Is the first step when compar­
ing costs of different services. 
Estimates the cost of delivering 
all alcoholism treatment 
services in a setting; estimates 
the resources needed to 
provide the treatment and 
the monetary value of the 
resources to society, govern­
ment funding agencies, treat­
ment providers, and other 
stakeholders. 
Needs to include value of volunteered 
goods or labor to be informative. 
Relies on systematic data collection 
tools: 
• Drug Abuse Treatment Cost 
Analysis Program (DATCAP)—the 
first such tool used; estimates total 
and per-patient costs of an alcohol 
and other drug abuse treatment. 
• Substance Abuse Services Cost 
Analysis Program (SASCAP)— 
collects data on program costs 
and revenues as well as on direct 
and indirect labor costs. 
Cost-Effectiveness Analysis (CEA) 
Compares two or more 
treatments using a cost-
effectiveness ratio—the 
difference in costs between 
two interventions divided by 
the difference in outcomes. 
Is a measure of how much 
more it costs to achieve one 
unit of outcome with one 
treatment program than with 
another. 
Usefulness depends on which 
outcome is analyzed because cost-
effectiveness ratios for different 
treatment outcomes may have 
different policy implications. To 
address this issue, a common 
metric can be used: the quality-
adjusted life year (QALY). 
Cost–Benefit Analysis (CBA) 
Calculates the costs of treat-
ment; also places a dollar 
value on all outcomes. 
Can show which programs 
have benefits that exceed 
their costs. 
Directly compares the costs 
of treatment with the mone-
tary value of the outcomes. 
Combines all outcomes studied 
into one measure. 
CBAs measure both costs and out-
comes in monetary terms, which 
facilitates comparisons of alcoholism 
treatment services with other types of 
investments in health and well-being. 
CBAs usually put a dollar value on 
some outcomes, not all. 
Subtypes of CBAs include cost-
offset studies (which only consider 
future health care costs as benefits) 
and return-on-investment studies 
(which consider only benefits to the 
organization funding the treatment). 
Allows policymakers 
to identify critical cost 
components and 
facilitates sensitivity 
analyses that assess 
whether the results 
of a CEA or CBA are 
affected by changes 
in key assumptions. 
QALYs can compare a 
wide range of diverse 
programs. 
CEAs can yield a 
ranking of competing 
alternatives. 
CBAs can allow direct 
comparison of costs to 
benefits. May give 
clearer guidance than 
CEAs on which treat­
ment to adopt. 
Filling out the standardized cost 
instrument is burdensome for 
researchers and program staff. 
QALYs are difficult to measure, 
especially for services expected to 
have small effects. 
CEAs do not provide information 
on the value of a program 
independent of alternatives. 
Many outcome measures cannot 
be expressed in dollars. 
Some variables could be consid-
ered either benefits or costs. 
Benefits of some programs might 
be measured more readily than 
benefits of others, and some benefits 
may manifest only over several 
years after treatment. 
Results and implications depend 
on whether a narrow stakeholder 
(e.g., health care provider, health 
plan, employer) perspective or a 
broader societal perspective is used. 
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only future health care costs as the ben­
efits) and return-on-investment (ROI) 
studies (which typically monetize only 
benefits to the organization that funded 
the treatment). Because CBAs combine 
multiple outcomes into a single measure 
and allow direct comparison of costs to 
benefits, they often provide clearer 
guidance than CEAs on which treat­
ment programs should be adopted— 
namely, those programs whose benefits 
exceed their costs. CEAs, in contrast, 
provide a ranking of competing alter­
natives but do not provide information 
on the extrinsic value of a treatment 
program independent of the alternatives. 
Various methods can be used to 
compare the benefits of a program with 
its costs. The two most commonly used 
methods are: 
•	 Net benefit measures, in which the 
costs are subtracted from the benefits 
•	 Benefit–cost ratios, in which the 
benefits are expressed as a percentage 
of the program costs. 
The choice of CBA measure is largely 
driven by the context in which the 
analysis is conducted and by the audience 
for which the analysis is performed. 
Some authors caution against using a 
benefit–cost ratio approach, however, 
because deciding whether a given vari­
able is considered a cost or a benefit 
can have a large impact on the final 
benefit–cost ratio (Drummond et al. 
1997). For example, if a researcher 
considers car crashes a cost of alcohol 
use, then the dollar value of the car 
crashes suffered by a treatment program’s 
participants could be considered a cost 
of that program, and therefore would 
be included in the denominator of the 
benefit–cost ratio. Conversely, the 
researcher could consider avoided car 
crashes a benefit of the treatment pro­
gram, in which case the dollar value of 
avoided car crashes would be included 
in the numerator of the benefit–cost 
ratio. Obviously, the final value of the 
benefit–cost ratio can differ greatly 
depending on whether the costs associ­
ated with car crashes are included in 
the numerator or the denominator. For 
this reason, it is suggested that analysts 
use the net benefit approach.  
CBAs are not always easy to imple­
ment. For example, it may be challeng­
ing to estimate dollar values for all 
outcomes of the interventions because 
many clinically relevant outcomes can­
not be expressed in dollars (e.g., reduced 
levels of alcohol use). Furthermore, it 
may not be possible to measure all rele­
vant outcomes of an intervention, lead­
ing to an underestimate of the benefits 
of some interventions. If the benefits of 
one program can be monetized more 
readily than those of another program, 
a CBA of both programs may yield 
misleading results, and the wrong 
intervention may be adopted. 
Because the choice of outcome mea­
sures can have such a great influence 
on the results of a CBA, researchers 
who want to conduct CBAs should 
examine the literature on the social 
costs of alcohol-related problems for 
guidance on which outcomes to mea­
sure and how to monetize them (e.g., 
Harwood et al. 1998). This approach 
ensures a minimal level of comparability 
across CBAs of varying alcohol services. 
Another challenge with CBAs is 
that many of the benefits of alcohol 
services manifest over several years after 
treatment. Therefore, it is important 
that researchers who take into account 
future benefits (and costs) present all 
costs and benefits at their present value— 
an approach called discounting. Several 
texts provide guidance on the process 
of discounting and the choice of the 
discount rate to adjust future costs and 
benefits to their present value (e.g., Gold 
et al. 1996; Drummond et al. 1997). 
Another key issue is the perspective 
from which the CBA is conducted. 
Historically, many CBAs of alcohol 
services have been conducted from the 
narrow perspective of one or more key 
stakeholders (i.e., employers, health 
plans, and State governments)—that is, 
the analysis included only costs and 
benefits to these stakeholders. For 
example, one form of CBA that has 
been widely used in the alcohol services 
research field is cost-offset analysis 
(Holder and Blose 1986, 1992; Holder 
and Hallan 1986; Goodman et al. 1991, 
2000; Booth et al. 1997; Parthasarathy 
et al. 2001; Kane et al. 2004). Although 
the definition of “cost-offset” has varied 
among studies, the term suggests that 
the cost of alcoholism treatment may 
be offset by a reduction in future medical 
care use and health care costs (Holder 
and Blose 1992). Thus, these studies 
look at a narrowly defined net benefit 
of alcoholism treatment that considers 
only reductions in future health care uti­
lization as the benefits of such treatment. 
In contrast, Gold and colleagues 
(1996) strongly recommend that analysts 
adopt a broader societal perspective. In 
line with this recommendation, Fleming 
and colleagues (2000) applied the CBA 
approach to Project Trial for Early 
Alcohol Treatment (TrEAT), in which 
physicians administered brief interven­
tions to problem drinkers in a randomized 
controlled trial. The authors performed 
the CBA both from a medical care sys­
tem perspective and from a societal per­
spective. In this approach, the medical 
care perspective considered the decrease 
in future emergency department visits 
and hospitalizations as benefits, whereas 
the societal benefits perspective incor­
porated other benefits, such as reduc­
tions in alcohol-related traffic crashes, 
crimes, and legal proceedings. (See the 
article by Mundt in this issue for more on 
the economic analysis of Project TrEAT.) 
Both narrow stakeholder perspectives 
and the broader societal perspective 
can yield useful results. For example, 
the societal perspective improves com­
parability across studies by providing a 
common perspective. Enumerating and 
monetizing all socially relevant outcomes, 
however, often is difficult. Furthermore, 
not all social outcomes are relevant to 
all stakeholders that sponsor alcohol 
services. Health care providers, work­
places, and schools all make decisions 
on funding alcohol services and have 
outcomes and costs that are unique to 
their organizations. Thus, both narrow 
stakeholder perspectives and a broader 
societal perspective are necessary to inform 
alcohol policy and service adoption. 
Conclusions 
Because of the enormous social costs they 
impose, alcohol abuse and dependence 
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as well as other alcohol-related problems 
are of major concern to policymakers 
and researchers, and considerable 
research into the effectiveness of alco­
holism treatment has been performed as 
a result. Yet increasing health care costs 
demand that these treatments be cost-
effective as well as efficacious. In light 
of the increased need for and emphasis 
on understanding the economic value of 
alcoholism treatment, economic analyses 
are playing a more prominent role in 
alcohol services research. Although 
previous research into the cost, cost-
effectiveness, and cost–benefit of alcohol 
services has provided critically impor­
tant and policy-relevant information, 
three emerging issues suggest that yet 
more economic evaluations of alco­
holism treatment services are needed. 
First, and perhaps foremost, as new 
treatment alternatives are developed, 
ongoing economic analyses must exam­
ine not only these new therapies but 
also existing therapies, both alone and 
in combination with the new therapies. 
For example, NIAAA has funded 
a CEA of the treatment approaches 
included in COMBINE, a multisite, 
randomized controlled trial that is assess­
ing the efficacy of two pharmacothera­
pies (i.e., naltrexone and acamprosate) 
and psychotherapy, individually and in 
combination, in the treatment of alco­
hol dependence. COMBINE is one of 
the most ambitious clinical trials of 
alcoholism treatment ever undertaken, 
and its ancillary CEA should yield 
invaluable information on the costs and 
cost-effectiveness of combining behav­
ioral therapies and pharmacotherapies 
for treating alcohol dependence. Many 
novel treatment approaches (e.g., phar­
macotherapies, motivational interview­
ing) have promise both as stand-alone 
treatments and as additional services 
that can improve the effectiveness of 
existing treatment modalities. Therefore, 
ongoing economic evaluations of all 
available treatment options are neces­
sary to ensure that scarce treatment 
resources are used most efficiently. 
Second, recent improvements in 
economic costing methodologies com­
bined with the relative lack of formal 
cost studies in the literature suggest 
that much more research is needed into 
the economic cost of existing alcoholism 
treatment services. Because many stud­
ies have used DATCAP to estimate the 
cost of AOD abuse treatment programs, 
further cost analyses of new alcoholism 
treatment methods using this approach 
may be needed so that the findings can 
be compared with findings in the exist­
ing literature. However, it is equally if 
not more important that cost studies be 
conducted using newer costing meth­
ods, such as SASCAP. Using these newer 
methods, cost studies can provide criti­
cal information on the cost of individual 
treatment services across modalities. 
This information will both improve 
allocation decisions and inform the next 
generation of CEA and CBA studies. 
Finally, recent studies suggest that 
CEAs may be biased against less intensive 
forms of treatment if the effectiveness 
of treatment varies systematically with 
the severity of the patient’s condition 
(Bray et al. 2004). Many previous stud­
ies on the cost-effectiveness of alcohol 
services have compared the outcomes 
of patients receiving more intensive 
treatment services, such as inpatient 
care, with those of patients receiving 
less intensive treatment, such as partial 
hospitalization, and concluded that less 
intensive treatments are more cost-
effective. If the effect of treatment 
depends on patient severity, however, it 
is possible that the outcomes obtained 
with patients in less intensive modali­
ties (whose condition typically is less 
severe) could not be replicated if patients 
with more severe conditions were assigned 
to these modalities. In this case, CEA 
studies may underestimate the differential 
benefit of the more intensive treatment 
and for this reason may falsely conclude 
that less intensive care is more cost-
effective. Therefore, the next genera­
tion of CEAs in alcohol service research 
must incorporate a deeper appreciation 
of the possible variability of treatment 
effects for various patient subgroups.  
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